Note

pubs.acs.org/joc

Enantioselective N‑Heterocyclic Carbene-Catalyzed Synthesis of
Triﬂuoromethyldihydropyridinones
Kun-Quan Chen,
Dong-Ling Wang,
†
Marine College, Shandong University at Weihai, 180 Wenhua West Road, Weihai 264209, China
‡
Beijing National Laboratory for Molecular Science, Key Laboratory of Molecular Recognition and Functional, Institute of Chemistry,
Chinese Academy of Sciences, Beijing 100190, China
*S Supporting Information

De-Qun Sun,*,†

and Song Ye*,‡

†,‡

†,‡

Zhi-Qin Liang,

‡

ABSTRACT: The enantioselective N-heterocyclic carbene-
catalyzed [4 + 2] cyclocondensation of α-chloroaldehydes and
triﬂuoromethyl N-Boc azadienes was developed, giving the
corresponding 3,4-disubstituted-6-triﬂuoromethyldihydropyri-
din-2(1H)-ones in good yields with exclusive cis-selectivities
and excellent enantioselectivities.

I ncorporation of ﬂuorine into molecules can bring notable

changes in physical and chemical properties.1 Among them,
triﬂuoromethyl group is one of the most important ﬂuorine-
containing functional groups for its addition of metabolic
stability and lipophilicity.2 On the other hand, dihydropyr-
idinones are widely present in various bioactive compounds.3
Combined with these two features, triﬂuoromethyldihydropyr-
idinone would be an interesting target for organic synthesis.4
In the past decades, N-heterocyclic carbenes (NHCs) have
been demonstrated as eﬃcient organocatalysts for a wide
reactions of aldehydes,5 epoxy aldehydes,6 α-
variety of
haloaldehdyes,7 enals,8 ketenes,9 esters,10 Michael acceptors,11
and others.12 The hetero-Diels−Alder (HDA) reactions of 1-
azadienes are powerful approaches to the synthesis of six-
membered N-heterocycles.13 The NHC-catalyzed cyclization
reactions with azadienes for the synthesis of N-heterocycles
have also been reported, including the reaction of enals with
azadienes by Bode et al.14 and the reaction of esters with
azadienes by Chi et al.15 The NHC-catalyzed [4 + 2]
cyclization reaction of ketenes and chloroaldehydes with
azadienes was developed in our group.16 Considering the
importance of triﬂuoromethylated compounds, we are inter-
ested in the NHC-catalyzed synthesis of triﬂuoromethylated
heterocycles.17 In this paper, we report the enantioselective
synthesis of triﬂuoromethylated dihydropyridinones.18
<para sub=“opt”>
Initially, the reaction of α-chloroaldehyde 1a and triﬂuor-
omethyl azadiene 2a was investigated under NHC catalysis
(Table 1). Although the NHC-catalzyed reaction of ketene or
α-chloraldehyde with triﬂuoromethyl azadiene gave no or only
a trace of the desired cycloadduct, we were encouraged to ﬁnd
that the reaction of chloroaldehyde 1a catalyzed by tetracyclic
NHC A1′19 gave the desired triﬂuoromethyl dihydropyridinone
3a in 26% yield with 92% ee (entry 1). Various bases were then
screened for the reaction (entries 1−5). It is interesting that
DIPEA aﬀorded the best enantioselectivity, while Cs2CO3 was
the best choice for yield. Considering the two roles of the

base(s) to deprotonate the NHC precursor and remove the
hydrochloride, mixed bases were then investigated. We were
happy to ﬁnd that both the yield and enantioselectivity were
improved when the mixed bases of Cs2CO3 (0.1 equiv) and
DIPEA (3.0 equiv) were employed for the reaction (entry 6).
NHC precursor A2 and A3 with diﬀerent N-substituents
resulted in low yields (entries 7 and 8). Both the reactions
using NHC precursor B derived from L-pyroglutamic acid and
the NHC precursor C with a free hydroxyl group gave only
trace of
the desired cycloadduct (entries 9 and 10).
Optimization of solvents showed that 1,4-dioxane was the
best (entries 11 and 12). Further improvements were realized
when 4 Å molecular sieves (4 Å MS) was added, giving the
desired triﬂuoromethyl dihydropyridinone 3a in 86% yield with
99% ee (entry 13). Reducing the loading of NHC precursor to
5 mol % resulted in some loss of the yield but without erosion
of the enantioselectivity (entry 14).
</para>
<para sub="scope">
With the optimized condition in hand, a variety of azadienes
was investigated for the reaction (Table 2). Both azadienes with
electron-donating groups (Ar = 4-MeC6H4, 4-MeOC6H4) and
with electron-withdrawing groups (Ar = 4-ClC6H4, 4-BrC6H4)
worked well, giving the desired dihydropyridinones (3b−3d) in
good yields with exclusive cis-selectivities and excellent
enantioselectivities. Substituents at the meta-position (Ar = 3-
MeC6H4, 3-ClC6H4) and ortho-position (Ar = 2-MeC6H4, 2-
ClC6H4) were also well tolerated, giving the dihydropyridi-
nones (3f−3i) in slightly decreased yields with high
enantioselectivities. The azadiene with 2-furyl group aﬀorded
in 78% yield with 99% ee. Notably, α-
cycloadduct 3j
chloroaldehydes with varied linear aliphatic chains reacted
well, giving the desired cycloadducts (3k−3p) in good to high
yields with exclusive diastereo- and excellent enantioselectiv-
</para>
Received:
Published: May 1, 2015

January 31, 2015

© 2015 American Chemical Society

5900

DOI: 10.1021/acs.joc.5b00232
J. Org. Chem. 2015, 80, 5900−5905

The Journal of Organic Chemistry

Note

Table 1. Optimization of Reaction Conditions

Table 2. Reaction Scope

basea

solvent

yield (%)b

ee (%)c

cat
A1
A1
A1
A1
A1
A1
A2
A3
B
C
A1
A1
A1
A1

DIPEA
K2CO3
Cs2CO3
Et3N
DMAP
Cs2CO3, DIPEA
Cs2CO3, DPIEA
Cs2CO3, DIPEA
Cs2CO3, DIPEA
Cs2CO3, DIPEA
Cs2CO3, DIPEA
Cs2CO3, DIPEA
Cs2CO3, DIPEA
Cs2CO3, DIPEA

entry
1
2
3
4
5
6
7
8
9
10
11
12
13d
14f
aOne base (3.0 equiv) for entries 1−5, or mixed bases of Cs2CO3 (0.1
equiv) and DIPEA (3.0 equiv) for entries 6−14. bIsolated yield.
cDetermined by chiral HPLC. d4 Å MS (50 mg) was added. fNHC
precursor (5 mol %) was employed.

DCM
DCM
DCM
DCM
DCM
DCM
DCM
DCM
DCM
DCM
THF
1,4-dioxane
1,4-dioxane
1,4-dioxane

26
36
40
13
20
61
19
19
trace
trace
65
77
86
71

92
90
89
87
90
99
99
99
ND
ND
98
99
99
99

aIsolated yield with dr > 20:1 for all cases.
<para sub="scope">
ities. In addition, α-chloroaldehyde with branched aliphatic
chain could give the corresponding annulation product
in
excellent enantioselectivity albeit in low yield (3q).
</para>
<para sub=“props”>
The absolute conﬁguration of cycloadduct 3e was

determined by the X-ray analysis of its crystal (Figure S1).
</para>
<para sub="scope">
Although the inverse-electron-demanded DA reactions with
N-tosyl azadienes have been well established in literatures, the
corresponding reaction with N-Boc azadienes remains unex-
plored. In our work, the N-Boc azadienes 2 were successfully
employed, as expected, and the protective Boc group could be
easily removed by TFA in DCM, giving the corresponding
dihydropyridinone 4a in 99% yield without the erosion of
enantioselectivity (eq 1).
</para>
<para sub=“ques”>
A plausible catalytic cycle for the reaction is depicted in
Figure 1. The addition of NHC catalyst to chloroaldehyde 1
gives the zwitterionic intermediate I,20 which is converted to
the corresponding enolate II by elimination of hydrogen
chloride in the presence of base. The [4 + 2] cycloaddition of
enolate II and triﬂuoromethyl azadiene 2 aﬀords the cyclo-
adduct III. The fragmentation of cycloadduct III aﬀords the
</para>
Figure 1. Plausible catalytic cycle.
<para sub=“ques”>
ﬁnal dihydropyridinone 3 and regenerates the NHC catalyst. It
should be noted that an alternative pathway via stepwise
Michael addition of enolate II to azadiene followed by
intramolecular amidation is also possible. However,
the
exclusive cis-selectivities observed make us believe that the
</para>
5901

DOI: 10.1021/acs.joc.5b00232
J. Org. Chem. 2015, 80, 5900−5905

The Journal of Organic Chemistry
<para sub=“ques”>
concerted [4 + 2] cycloaddition is favored over the stepwise
pathway.
</para>
<para sub=“ques”>
The possible stereocontrol mode via endo-selectivity Diels−
Alder reaction is depicted in Figure 2. When the R group in
enals is an aryl group, the π-stacking of the two aryl groups in
enal and azadiene favors the endo-selectivity.
</para>
Figure 2. Possible stereochemical mode.

In summary, the enantioselective N-heterocyclic carbene-
catalyzed [4 + 2] cyclocondensation of α-chloroaldehydes and
triﬂuoromethyl N-Boc azadienes was developed. The reaction
for both aryl and aliphatic α-chloroaldehydes,
worked well
giving the corresponding 3,4-disubstituted-6-triﬂuoromethyl
dihydropyrindinones
in good yields with exclusive cis-
selectivities and excellent enantioselectivities.

■ EXPERIMENTAL SECTION
<para sub=“exp”>
General Methods. Unless otherwise indicated, all reactions were
carried out under nitrogen atmosphere in oven-dried glassware with
magnetic stirring. All solvents were dried and distilled by standard
procedures. NHC precursors, chloroaldehydes, and triﬂuoromethyl
substituted α,β-unsaturated imines were prepared according to
literatures.21 Column chromatograph was performed on silica gel
200−300 mesh.

Typical Procedure. To an oven-dried 50 mL Schlenk tube
equipped with a stir bar was charged with precatalyst A1 (14.0 mg,
0.03 mmol) and anhydrous Cs2CO3 (9.7 mg, 0.03 mmol). This tube
was closed with a septum, evacuated, and backﬁlled with argon. To this
mixture was added freshly distilled 1,4-dioxane (2 mL) while stirring
for several minutes at room temperature, then DIPEA (218 μL, 0.6
mmol), chloroaldehyde 1a (109.64 mg, 0.6 mmol), and triﬂuor-
omethyl azadiene 2a (89.8 mg, 0.3 mmol) were added. After stirring
for 24 h, the reaction mixture was diluted with diethyl ether and passed
through a short silica pad. The solvent was removed under reduced
pressure, and the residue was puriﬁed by chromatography on silica gel
(ethyl acetate/petroleum ether, typically 1/100) to give the desired
cycloadduct 3.

Racemic samples for the chiral phase HPLC analysis were prepared
using triazolium D as the NHC precatalyst under the same conditions.

(3S,4S)-tert-Butyl3-benzyl-2-oxo-4-phenyl-6-(triﬂuoromethyl)-
3,4-dihydropyridine-1(2H)-carboxylate (3a). Colorless oil, 111.2 mg,
86%. Rf = 0.5 (hexane/EtOAc = 10:1), [α]D
20 +175.0 (c 1.0, CHCl3),
HPLC analysis: 99% ee [Daicel CHIRALPAK AD-H column, 20 °C,
254 nm hexane/i-PrOH = 95:5, 0.5 mL/min, 254 nm, 10.3 min
(major), 12.5 min (minor)]. 1H NMR (400 MHz, CDCl3): δ 7.35−
7.20 (m, 7H), 7.12−7.10 (m, 4H), 6.27 (d, J = 7.2 Hz, 1H), 3.60 (t, J =
6.3 Hz, 1H), 3.27−3.20 (m, 2H), 2.37−2.30 (m, 1H), 1.60 (s, 9H).
13C NMR (100 MHz, CDCl3): δ 170.0, 149.9, 138.7, 135.3, 130.2,
130.1, 129.9 (q, J = 35.1 Hz), 129.5, 129.2, 129.1, 128.7, 128.7, 128.3,
126.7, 121.8, 119.4 (q, J = 4.2 Hz), 119.3, 119.1, 86.0, 47.2, 40.5, 31.7,
29.8, 27.5. 19F NMR (471 MHz, CDCl3) δ −63.24 (s). IR (KBr):
3566, 3030, 2982, 2933, 1783, 1715, 1144, 698. HRMS (ESI) m/z: [M
+ Na]+ calcd for C24H24F3NO3Na+, 454.15921; found, 454.16005.
</para>
Note
<para sub=“exp”>
(3S,4S)-tert-Butyl3-benzyl-2-oxo-4-(p-tolyl)-6-(triﬂuoromethyl)-
3,4-dihydropyridine-1(2H)-carboxylate (3b). Colorless oil, 115.6 mg,
85%. Rf = 0.4 (hexane/EtOAc = 10:1), [α]D
20 +172.7 (c 1.0, CHCl3),
HPLC analysis: 99% ee [Daicel CHIRALPAK AD-H column, 20 °C,
254 nm hexane/i-PrOH = 95:5, 0.5 mL/min, 254 nm, 9.7 min
(major), 11.1 min (minor)]. 1H NMR (400 MHz, CDCl3): δ 7.20 (t, J
= 7.3 Hz, 2H), 7.18−7.15 (m, 1H), 7.05 (t, J = 7.3 Hz, 4H), 7.93 (d, J
= 8.1 Hz, 2H), 6.18 (d, J = 7.3 Hz, 1H), 3.49 (t, J = 6.2 Hz, 1H),
3.19−3.11 (m, 2H), 2.30−2.23 (m, 4H), 1.52 (s, 9H). 13C NMR (100
MHz, CDCl3): δ 169.9, 149.8, 138.7, 138.0, 132.0, 130.3, 129.9, 129.8,
129.6, 129.0, 128.6 (q, J = 35.0 Hz), 128.4, 126.5, 119.5 (q, J = 4.1
Hz), 119.0, 85.8, 47.2, 40.0, 31.5, 27.4, 21.1. IR (KBr): 3566, 3029,
2982, 1783, 1716, 1146, 699. HRMS (ESI) m/z: [M + Na]+ calcd. for
C25H26F3NO3Na+, 468.17493; found, 488.17570.

(3S,4S)-tert-butyl3-benzyl-4-(4-methoxyphenyl)-2-oxo-6-(triﬂuor-
omethyl)-3,4-dihydropyridine-1(2H)-carboxylate (3c). Colorless oil,
110.0 mg, 77%. Rf = 0.3 (hexane/EtOAc = 10:1), [α]D
20 +193.6 (c 1.0,
CHCl3), HPLC analysis: 99% ee [Daicel CHIRALPAK AD-H column,
20 °C, 254 nm hexane/i-PrOH = 95:5, 0.5 mL/min, 254 nm, 11.2 min
(major), 14.4 min (minor)]. 1H NMR (400 MHz, CDCl3): δ 7.34−
7.28 (m, 2H), 7.24−7.21 (m, 1H), 7.13−7.11 (m, 2H), 7.04−7.01 (m,
2H), 6.87−6.84 (m, 2H), 6.25 (d, J = 7.3 Hz, 1H), 3.81 (s, 3H), 3.54
(t, J = 6.4 Hz, 1H), 3.27−3.17 (m, 2H), 2.37−2.31 (m, 1H), 1.58 (s,
9H). 13C NMR (100 MHz, CDCl3): δ 170.0, 159.5, 150.0, 138.7,
129.8, 129.7, 129.5, 129.2 (d, J = 34.9 Hz), 129.0, 128.8, 128.7, 128.6,
127.4, 127.3, 126.9, 126.5, 121.7, 119.6 (d, J = 4.1 Hz), 119.0, 114.5,
85.8, 55.3, 47.2, 39.6, 31.6, 27.4. IR (KBr): 3545, 2929, 2856, 1784,
1716, 1147, 699. HRMS (ESI) m/z: [M + Na]+ calcd for
C25H26F3NO4Na+, 484.17007; found, 484.17061.

(3S,4S)-tert-Butyl3-benzyl-4-(4-chlorophenyl)-2-oxo-6-(triﬂuoro-
methyl)-3,4-dihydropyridine-1(2H)-carboxylate (3d). Colorless oil,
92.5 mg, 66%. Rf = 0.5 (hexane/EtOAc = 10:1), [α]D
20 +131.5 (c 1.0,
CHCl3), HPLC analysis: 96% ee [Daicel CHIRALPAK AD-H column,
20 °C, 254 nm hexane/i-PrOH = 95:5, 0.5 mL/min, 254 nm, 11.2 min
(major), 12.3 min (minor)]. 1H NMR (400 MHz, CDCl3): δ 7.22−
7.16(m, 5H), 7.05−7.01 (m, 3H), 6.91 (dt, J = 7.0, 1.5 Hz, 1H), 6.17
(d, J = 7.4 Hz, 1H), 3.52−3.48 (m, 1H), 3.17 (dd, J = 12.5, 7.8 Hz,
2H), 2.28−2.21 (m, 1H), 1.53 (s, 9H) 13C NMR (100 MHz, CDCl3):
δ 169.5, 149.4, 138.3, 137.2, 135.0, 130.4 (q, J = 35.2 Hz), 129.0,
128.8, 128.7, 128.6, 126.9, 126.8, 118.8, 118.7 (q, J = 4.1 Hz), 86.4,
47.0, 40.0, 31.7, 27.5. IR (KBr): 3566, 2961, 2935, 1784, 1716, 1146,
699. HRMS (ESI) m/z: [M + Na]+ calcd for C24H23ClF3NO3Na+,
488.12039; found, 488.12108.

(3S,4S)-tert-butyl3-benzyl-4-(4-bromophenyl)-2-oxo-6-(triﬂuoro-
methyl)-3,4-dihydropyridine-1(2H)-carboxylate (3e). Colorless oil,
122.5 mg, 80%. Rf = 0.4 (hexane/EtOAc = 10:1), [α]D
20 +200.0 (c 1.0,
CHCl3), HPLC analysis: 99% ee [Daicel CHIRALPAK AD-H column,
20 °C, 254 nm hexane/i-PrOH = 95:5, 0.5 mL/min, 254 nm, 10.1 min
(major), 11.6 min (minor)]. 1H NMR (400 MHz, CDCl3): δ 7.46 (d, J
= 8.4 Hz, 2H), 7.31 (t, J = 7.3 Hz, 2H), 7.29−7.24 (m, 1H), 7.11 (d, J
= 7.4 Hz, 2H), 6.97 (d, J = 8.3 Hz, 2H), 6.24 (d, J = 7.3 Hz, 1H), 3.56
(t, J = 6.5 Hz, 1H), 3.29−3.21 (m, 2H), 2.34−2.26(m, 1H), 1.60 (s,
9H). 13C NMR (100 MHz, CDCl3): δ 169.6, 149.7, 138.2, 134.2,
132.2, 130.5, 130.2, 130.1, 130.0, 128.9, 128.7 (q, J = 34,9 Hz),, 128.5,
126.7, 122.3, 121.6, 118.8, 118.6 (q, J = 4.2 Hz)., 86.1, 46.7, 39.7, 31.5,
27.4. 19F NMR (471 MHz, CDCl3): δ −63.38 (s). IR (KBr): 3566,
3029, 2982, 1783, 1716, 1144, 699. HRMS (ESI) m/z: [M + Na]+
calcd for C24H23BrF3NO3Na+, 532.06958; found, 532.07056.

(3S,4S)-tert-Butyl3-benzyl-2-oxo-4-(m-tolyl)-6-(triﬂuoromethyl)-
3,4-dihydropyridine-1(2H)-carboxylate (3f). Colorless oil, 78.8 mg,
58%. Rf = 0.5 (hexane/EtOAc = 10:1), [α]D
20 +158.2 (c 1.0, CHCl3),
HPLC analysis: 99% ee [Daicel CHIRALPAK AD-H column, 20 °C,
254 nm hexane/i-PrOH = 95:5, 0.5 mL/min, 254 nm, 9.3 min
(major), 10.3 min (minor)]. 1H NMR (400 MHz, CDCl3): δ 7.22 (t, J
= 7.3 Hz, 2H), 7.17−7.11 (m, 2H), 7.03 (d, J = 7.2 Hz, 3H), 6.80 (d, J
= 6.0 Hz, 2H), 6.18 (d, J = 7.3 Hz, 1H), 3.37 (dd, J = 17.9, 11.8 Hz,
1H), 3.18−3.01 (m, 2H), 2.27−2.23 (m, 4H), 1.52 (d, J = 6.6 Hz,
9H). 13C NMR (100 MHz, CDCl3): δ 169.9, 149.9, 138.8, 138.8,
135.2, 130.2, 129.9 (q, J = 35.0 Hz), 129.5, 129.2, 129.1, 129.0, 128.7,
126.7, 125.8, 121.8, 119.6 (q, J = 4.1 Hz), 119.1, 40.5, 31.7, 27.5, 21.6.
</para>
5902

DOI: 10.1021/acs.joc.5b00232
J. Org. Chem. 2015, 80, 5900−5905

The Journal of Organic Chemistry

Note
<para sub=“exp”>
IR (KBr): 3566, 3218, 2960, 1688, 1507, 1298, 698. HRMS (ESI) m/
z: [M + Na]+ calcd for C25H26F3NO3Na+, 468.17508;
found,
468.17570.

(3S,4S)-tert-Butyl3-benzyl-4-(3-chlorophenyl)-2-oxo-6-(triﬂuoro-
methyl)-3,4-dihydropyridine-1(2H)-carboxylate (3g). Colorless oil,
82.2 mg, 59%. Rf = 0.5 (hexane/EtOAc = 10:1), [α]D
20 +257.7 (c 1.0,
CHCl3), HPLC analysis: 97% ee [Daicel CHIRALPAK AD-H column,
20 °C, 254 nm hexane/i-PrOH = 95:5, 0.5 mL/min, 254 nm, 11.6 min
(major), 12.9 min (minor)]. 1H NMR (400 MHz, CDCl3): δ 7.24−
7.15 (m, 5H), 7.06−7.01 (m, 3H), 6.92 (dd, J = 4.2, 2.8 Hz, 1H), 6.18
(d, J = 7.4 Hz, 1H), 3.50 (t, J = 6.2 Hz, 1H), 3.22−3.14 (m, 2H),
2.28−2.21 (m, 1H), 1.53 (s, 9H) 13C NMR (100 MHz, CDCl3): δ
169.3, 149.3, 138.2, 137.1, 135.0, 130.8, 130.5, 130.3, 129.0, 128.7 (q, J
= 35.1 Hz), 128.5, 126.8, 126.7, 121.6, 118.9, 118.7, 118.6 (q, J = 4.3
Hz), 86.3, 46.8, 39.9, 31.6, 27.4. IR (KBr): 3566, 3029, 2984, 1785,
1716, 1145, 698. HRMS (ESI) m/z: [M + Na]+ calcd for
C24H23ClF3NO3Na+, 488.12009; found, 488.12108.

(3S,4S)-tert-Butyl3-benzyl-2-oxo-4-(o-tolyl)-6-(triﬂuoromethyl)-
3,4-dihydropyridine-1(2H)-carboxylate (3h). Colorless oil, 78.8 mg,
58%. Rf = 0.5 (hexane/EtOAc = 10:1), [α]D
20 +166.0 (c 1.0, CHCl3),
HPLC analysis: 99% ee [Daicel CHIRALPAK AD-H column, 20 °C,
254 nm hexane/i-PrOH = 95:5, 0.5 mL/min, 254 nm, 9.9 min
(major), 13.2 min (minor)]. 1H NMR (400 MHz, CDCl3): δ 7.18−
7.08 (m, 8H), 6.84−6.82(m, 2H), 6.09 (d, J = 6.9 Hz, 1H), 3.78 (t, J =
6.8 Hz, 1H), 3.26−3.21 (m, 1H), 3.16−3.10 (m, 1H), 2.44−2.38 (m,
1H), 1.91 (s, 3H), 1.50 (s, 9H).13C NMR (101 MHz, CDCl3): δ
170.6, 149.8, 138.4, 136.2, 134.9, 131.1, 129.1, 128.9 (q, J = 35.1 Hz),
128.8, 128.7, 128.6, 127.9, 127.3, 127.0, 126.7, 121.7, 119.0, 117.9 (q, J
= 4.3 Hz), 117.7, 85.9, 74.5, 58.4, 45.9, 35.6, 31.8, 27.5, 19.6. IR (KBr):
3566, 3029, 2981, 1780, 1715, 1144, 699. HRMS (ESI) m/z: [M +
Na]+ calcd for C25H26F3NO3Na+, 468.17490; found, 468.17570.

(3S,4S)-tert-Butyl3-benzyl-4-(2-chlorophenyl)-2-oxo-6-(triﬂuoro-
methyl)-3,4-dihydropyridine-1(2H)-carboxylate (3i). Colorless oil,
95.0 mg, 68%. Rf = 0.5 (hexane/EtOAc = 10:1), [α]D
20 +144.8 (c 1.0,
CHCl3), HPLC analysis: 99% ee [Daicel CHIRALPAK AD-H column,
20 °C, 254 nm hexane/i-PrOH = 95:5, 0.5 mL/min, 254 nm, 9.3 min
(major), 15.3 min (minor)]. 1H NMR (400 MHz, CDCl3): δ 7.33 (dt,
J = 8.1, 1.6 Hz, 1H), 7.23−7.11 (m, 6H), 6.92−6.90 (m, 2H), 6.18 (d,
J = 6.9 Hz, 1H), 4.24 (td, J = 6.8, 1.6 Hz, 1H), 3.13 (dd, J = 14.1, 9.1
Hz, 2H), 2.52−2.45 (m, 1H), 1.49 (s, 9H) 13C NMR (101 MHz,
CDCl3): δ 170.1, 149.6, 138.4, 134.1, 130.2, 129.8, 129.5 (q, J = 35.0
Hz), 129.2, 128.9, 128.6, 128.4, 127.9, 126.6, 121.5, 118.8, 117.3 (q, J
= 4.3 Hz), 85.9, 46.2, 36.3,, 31.7, 27.3. IR (KBr): 3566, 3030, 2982,
1780, 1715, 1145, 699. HRMS (ESI) m/z: [M + Na]+ calcd for
C24H23ClF3NO3Na+, 488.12039; found, 488.12108.

(3S,4S)-tert-Butyl3-benzyl-4-(furan-2-yl)-2-oxo-6-(triﬂuorometh-
yl)-3,4-dihydropyridine-1(2H)-carboxylate (3j). Colorless oil, 98.6
mg, 78%. Rf = 0.5 (hexane/EtOAc = 10:1), [α]D
20 +139.9 (c 1.0,
CHCl3), HPLC analysis: 99% ee [Daicel CHIRALPAK AD-H column,
20 °C, 254 nm hexane/i-PrOH = 95:5, 0.5 mL/min, 254 nm, 10.7 min
(major), 14.8 min (minor)]. 1H NMR (400 MHz, CDCl3): δ 7.32 (d,
2.6 Hz, 1H), 7.25−7.22 (m, 2H), 7.17−7.12 (m, 3H), 6.27 (dd, J =
3.1, 1.9 Hz, 1H), 6.13 (dd, J = 9.7, 5.4 Hz, 2H), 3.59 (t, J = 6.4 Hz,
1H), 3.29−3.24 (m, 1H), 2.96−2.90 (m, 1H), 2.35 (dd, J = 14.4, 10.3
Hz, 1H), 1.49 (s, 9H). 13C NMR (100 MHz, CDCl3): δ 169.4, 149.4,
148.9, 143.0, 138.6, 131.7, 131.13 (q, J = 35.3 Hz), 129.2, 128.6, 126.6,
121.6, 118.9, 117.4 (q, J = 4.1 Hz), 110.6, 108.7,85.6, 47.6, 33.2, 32.0,
27.4. IR (KBr): 3545, 2929, 2856, 1784, 1716, 1147, 699. HRMS
(ESI) m/z: [M + Na]+ calcd for C22H22F3NO4Na+, 444.13898; found,
444.13931.

(3S,4S)-tert-Butyl2-oxo-4-phenyl-3-propyl-6-(triﬂuoromethyl)-
3,4-dihydropyridine-1(2H)-carboxylate (3k). Colorless oil, 61.9 mg,
53%. Rf = 0.7 (hexane/EtOAc = 10:1), [α]D
20 +113.0 (c 1.0, CHCl3),
HPLC analysis: 99% ee [Daicel CHIRALPAK AD-H column, 20 °C,
254 nm hexane/i-PrOH = 95:5, 0.5 mL/min, 254 nm, 8.8 min
(major), 11.8 min (minor)]. 1H NMR (400 MHz, CDCl3): δ 7.33−
7.25 (m, 3H), 7.18−7.16 (m, 2H), 6.32 (d, J = 6.3 Hz, 1H), 3.77 (dd, J
= 6.6, 5.4 Hz, 1H), 2.78 (q, J = 6.8 Hz, 1H), 1.62−1.58 (m, 10H),
1.44−1.37 (m, 2H), 1.37−1.11 (m, 1H), 0.87 (t, J = 7.3 Hz, 3H). 13C
NMR (100 MHz, CDCl3): δ 170.4, 150.1, 135.6, 130.2 (q, J = 34.9

Hz), 129.1, 128.3, 128.1, 121.9, 119.3, 119.2, 119.1 (q, J = 4.1 Hz),
85.8, 45.8, 41.5, 28.2, 27.5, 20.7, 14.1. IR (KBr): 3566, 2961, 2935,
1784, 1716, 1146, 699. HRMS (ESI) m/z: [M + Na]+ calcd for
C20H24F3NO3Na+, 406.15947; found, 406.16005.

(3S,4S)-tert-Butyl3-butyl-2-oxo-4-phenyl-6-(triﬂuoromethyl)-3,4-
dihydropyridine-1(2H)-carboxylate (3l). Colorless oil, 97.0 mg, 81%.
[α]D
20 +250.0 (c 1.0, CHCl3), HPLC analysis: 99% ee [Daicel
CHIRALPAK AD-H column, 20 °C, 254 nm hexane/i-PrOH = 95:5,
0.5 mL/min, 254 nm, 8.7 min (major), 11.6 min (minor)]. 1H NMR
(400 MHz, CDCl3): δ 7.23−7.17 (m, 3H), 7.11−7.08 (m, 2H), 6.24
(d, J = 6.9 Hz, 1H), 3.71−3.68 (m, 1H), 2.67 (t, J = 6.8 Hz, 1H),
1.55−1.54 (m, 1H), 1.50 (s, 9H), 1.32−1.26 (m, 4H), 1.22−1.17 (m,
1H), 0.77 (t, J = 7.2 Hz, 3H). 13C NMR (100 MHz, CDCl3): δ 170.4,
150.1, 135.6, 130.9, 130.5, 130.2 (q, J = 35.0 Hz), 129.8, 129.1, 128.3,
128.1, 124.6, 121.8, 119.2, 119.1 (q, J = 4.2 Hz), 85.7, 46.0, 41.4, 29.6,
27.5, 25.6, 22.7, 14.0. IR (KBr): 3545, 2929, 2857, 1784, 1716, 1147,
699. HRMS (ESI) m/z: [M + Na]+ calcd for C21H26F3NO3Na+,
420.17484; found, 420.17570.

(3S,4S)-tert-Butyl2-oxo-3-pentyl-4-phenyl-6-(triﬂuoromethyl)-
3,4-dihydropyridine-1(2H)-carboxylate (3m). Colorless oil, 122.6 mg,
99%. Rf = 0.7 (hexane/EtOAc = 10:1), [α]D
20 +139.0 (c 1.0, CHCl3),
HPLC analysis: 99% ee [Daicel CHIRALPAK AD-H column, 20 °C,
254 nm hexane/i-PrOH = 95:5, 0.5 mL/min, 254 nm, 8.7 min
(major), 11.5 min (minor)]. 1H NMR (400 MHz, CDCl3): δ 7.31−
7.25 (m, 3H), 7.18−7.16 (m, 2H), 6.32 (d, J = 6.9 Hz, 1H), 3.78−3.76
(m, 1H), 2.75 (q, J = 6.8 Hz, 1H), 1.62−1.58 (m, 1H), 1.58 (s, 9H),
1.41−1.35 (m, 2H), 1.28−1.25 (m, 4H), 1.24−1.21 (m, 1H), 0.87−
0.83 (m, 3H).13C NMR (100 MHz, CDCl3): δ 170.3, 150.0, 135.5,
130.8, 130.4, 130.1 (q, J = 34.9 Hz), 129.7, 129.0, 128.2, 128.0, 124.5,
121.7, 119.1 (q, J = 4.2 Hz), 119.0, 85.6, 45.9, 41.3, 31.7, 27.4, 27.0,
25.8, 22.4, 14.0. IR (KBr): 3566, 2932, 2859, 1783, 1716, 1146, 699.
HRMS (ESI) m/z: [M + Na]+ calcd for C22H28F3NO3Na+, 434.19070;
found, 434.19135.

(3S,4S)-tert-Butyl3-heptyl-2-oxo-4-phenyl-6-(triﬂuoromethyl)-
3,4-dihydropyridine-1(2H)-carboxylate (3n). Colorless oil, 141.5 mg,
99%. Rf = 0.7 (hexane/EtOAc = 10:1), [α]D
20 +84.9 (c 1.0, CHCl3),
HPLC analysis: 99% ee [Daicel CHIRALPAK AD-H column, 20 °C,
254 nm hexane/i-PrOH = 95:5, 0.5 mL/min, 254 nm, 8.1 min
(major), 11.7 min (minor)]. 1H NMR (400 MHz, CDCl3): δ 7.24−
7.18 (m, 3H), 7.11−7.08 (m, 2H), 6.25 (d, J = 6.8 Hz, 1H), 3.70 (dd, J
= 6.6, 5.5 Hz, 1H), 2.69 (q, J = 6.8 Hz, 1H), 1.59−1,48 (br, 11H),
1.33−1.28 (m, 2H), 1.21−1.15 (br, 9H), 1.07−1.04 (m, 1H), 0.80−
0.76 (m, 3H). 13C NMR (100 MHz, CDCl3): δ 170.3, 150.0, 135.5,
130.8, 130.4, 130.1 (q, J = 34.9 Hz), 129.7, 129.0, 128.2, 128.0, 124.4,
121.7, 119.1, 119.0 (q, J = 4.1 Hz), 116.3, 85.6, 45.9, 41.3, 31.7, 29.4,
29.0, 27.4, 27.3, 25.8, 22.6, 14.1. IR (KBr): 3536, 2929, 2857, 1783,
1716, 1147, 699. HRMS (ESI) m/z: [M + Na]+ calcd for
C24H32F3NO3Na+, 462.22187; found, 462.22265.

(3S,4S)-tert-Butyl3-nonyl-2-oxo-4-phenyl-6-(triﬂuoromethyl)-3,4-
dihydropyridine-1(2H)-carboxylate (3o). Colorless oil, 134.9 mg,
99%. Rf = 0.6 (hexane/EtOAc = 10:1), [α]D
20 +60.8 (c 1.0, CHCl3),
HPLC analysis: 99% ee [Daicel CHIRALPAK AD-H column, 20 °C,
254 nm hexane/i-PrOH = 95:5, 0.5 mL/min, 254 nm, 7.8 min
(major), 10.4 min (minor)]. 1H NMR (400 MHz, CDCl3): δ 7.25−
7.18 (m, 3H), 7.09 (dd, J = 9.9, 8.3 Hz, 2H), 6.25 (d, J = 6.8 Hz, 1H),
3.70 (dd, J = 6.5, 5.5 Hz, 1H), 2.69 (q, J = 6.8 Hz, 1H), 1.59−1.50 (br,
10H), 1.48−1.28 (m, 2H), 1.21−1.15 (m, 14H), 1.06−1.04 (m, 1H),
0.79 (t, J = 6.9 Hz, 3H). 13C NMR (100 MHz, CDCl3): δ 170.3, 150.0,
135.5, 130.8, 130.4, 130.1 (q, J = 34.9 Hz), 129.7, 129.0, 128.2, 128.0,
124.5, 121.7, 119.1 (q, J = 4.2 Hz), 119.0, 116.3, 85.6, 45.9, 41.3, 31.9,
29.5, 29.4, 29.3, 27.4, 27.3, 25.8, 22.7, 14.1. IR (KBr): 3566, 2961,
2935, 1784, 1716, 1146, 699. HRMS (ESI) m/z: [M + Na]+ calcd for
C26H36F3NO3Na+, 490.25303; found, 490.25395.

(3S,4S)-tert-Butyl3-decyl-2-oxo-4-phenyl-6-(triﬂuoromethyl)-3,4-
dihydropyridine-1(2H)-carboxylate (3p). Colorless oil, 139.0 mg,
96%. Rf = 0.6 (hexane/EtOAc = 10:1), [α]D
20 +117.7 (c 1.0, CHCl3),
HPLC analysis: 99% ee [Daicel CHIRALPAK AD-H column, 20 °C,
254 nm hexane/i-PrOH = 95:5, 0.5 mL/min, 254 nm, 7.8 min
(major), 10.0 min (minor)]. 1H NMR (400 MHz, CDCl3): δ 7.25−
7.17 (m, 3H), 7.09(d, J = 6.5 Hz, 2H), 6.24 (d, J = 6.8 Hz, 1H), 3.69
</para>
5903

DOI: 10.1021/acs.joc.5b00232
J. Org. Chem. 2015, 80, 5900−5905

The Journal of Organic Chemistry
<para sub=“exp”>
(t, J = 6.1 Hz, 1H), 2.68 (q, J = 6.8 Hz, 1H), 1.59−1.50 (br, 10), 1.44−
1.27 (m, 2H), 1.19−1.15 (br, 16H), 1.08−1.03 (m, 1H), 0.79 (t, J =
6.8 Hz, 3H). 13C NMR (100 MHz, CDCl3): δ 170.3, 150.0, 135.5,
130.8, 130.4, 130.1 (q, J = 35.0 Hz), 129.7, 129.0, 128.2, 128.0, 127.9,
121.7, 119.1 (q, J = 4.1 Hz), 119.0, 85.6, 45.9, 41.3, 31.9, 29.6, 29.5,
29.5, 29.4, 29.3, 27.4, 27.3, 25.8, 22.7, 14.1. IR (KBr): 3545, 2929,
2857, 1784, 1716, 1147, 699. HRMS (ESI) m/z: [M + Na]+ calcd for
C27H38F3NO3Na+, 504.26883; found, 504.26960.

(3S,4S)-tert-Butyl 3-isobutyl-2-oxo-4-phenyl-6-(triﬂuoromethyl)-
3,4-dihydropyridine-1(2H)-carboxylate (3q). Colorless oil, 25.0 mg,
21%.Rf = 0.7 (hexane/EtOAc = 10:1), [α]D
20 +135.5 (c 1.0, CHCl3),
HPLC analysis: 99% ee [Daicel CHIRALPAK IA column, 20 °C, 254
nm hexane/i-PrOH = 95:5, 0.5 mL/min, 254 nm, 8.3 min (major),
10.3 min (minor)]. 1H NMR (400 MHz, CDCl3) δ 7.26−7.14 (m,
5H), 6.25 (d, J = 6.9 Hz, 1H), 3.84 (t, J = 5.9 Hz, 1H), 2.46 (dd, J =
8.7, 6.3 Hz, 1H), 1.79−1.71 (m, 1H), 1.50 (s, 9H), 1.00 (d, J = 6.5 Hz,
3H), 0.82 (d, J = 6.7 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 170.2,
150.0, 136.3, 130.0,129.6 (d, J = 34.9 Hz), 129.0, 128.2, 127.9, 121.7,
119.8, 119.8 (d, J = 4.1 Hz). 119.0, 85.6, 52.3, 40.4, 27.4, 25.5, 22.0,
20.8. IR (KBr): 2982, 2934, 2874, 1782, 1713, 1144, 699. HRMS
(ESI) m/z: [M + Na]+ calcd for C20H24F3NO3Na+, 406.16054; found,
406.16005.

Removal of N-Boc. The solution of cycloadduct 3a (58 mg, 0.1
mmol) in 2 mL DCM containing TFA (113 uL, 1 mmol) was stirred
vigorously at 0 °C for 15 min, followed by at room temperature for 15
min. The reaction mixture was washed with saturated aqueous
NaHCO3, and the aqueous layer was back-extracted with DCM (2 × 2
mL). The organic layer was combined, dried over MgSO4, ﬁltered, and
concentrated under reduced pressure. The residue was puriﬁed by
column chromatography using 2% ethyl acetate in petroleum ether as
eluent to aﬀord the compound 4a as a white solid, mp 147−150 °C,
32.0 mg, 99%. Rf = 0.7 (n-hexane/EtOAc = 5:1), [α]D
20 +298.9 (c 1.0,
CHCl3), HPLC analysis: 99% ee [Daicel CHIRALPAK AD-H column,
20 °C, 254 nm hexane/i-PrOH = 95:5, 0.5 mL/min, 254 nm, 24.3 min
(major), 26.3 min (minor)]. 1H NMR (400 MHz, CDCl3): δ 7.79 (s,
1H), 7.22−7.11 (m, 6H), 7.02−6.97 (m, 4H), 5.84 (d, J = 6.3 Hz,
1H), 3.54 (t, J = 6.2 Hz, 1H), 3.25 (dd, J = 14.5, 5.0 Hz, 1H), 3.17−
3.11 (m, 1H), 2.31−2.23 (m, 1H). 13C NMR (100 MHz, CDCl3): δ
171.6, 139.0, 137.2, 129.1, 128.9, 128.5, 128.3, 128.0, 127.9, 127.5,
127.2 (q, J = 35.2 Hz), 126.8, 126.4, 121.5, 118.8, 112.1 (q, J = 4.4
Hz), 112.1, 46.0, 40.4, 31.3. 19F NMR (471 MHz, CDCl3) δ −70.43
(s). IR (KBr): 3566, 3218, 2960, 1688, 1507, 1298, 698. HRMS (ESI)
m/z: [M − H]− calcd for C19H15F3NO−, 330.11038;
found,
330.11003.
</para>
■ ASSOCIATED CONTENT
*S Supporting Information
X-ray data for cycloadduct 3h (CIF), NMR, and HPLC spectra
for obtained compounds. The Supporting Information is
available free of charge on the ACS Publications website at
DOI: 10.1021/acs.joc.5b00232.

■ AUTHOR INFORMATION
Corresponding Authors
*Email: dequn.sun@sdu.edu.cn
*Email: songye@iccas.ac.cn
Notes
The authors declare no competing ﬁnancial interest.

■ ACKNOWLEDGMENTS

Financial support from the Ministry of Science and Technology
of China (2011CB808600) and National Science Foundation
of China (21272237) is greatly acknowledged.

■ REFERENCES

(1) (a) Shimizu, M.; Hiyama, T. Angew. Chem., Int. Ed. 2005, 44, 214.
(b) Filler, R.; Kobayashi, Y.; Yagupolskii, L. M. Organo-fluorine

Note

Compounds
in Medicinal Chemistry and Biomedical Applications;
Elsevier: Amsterdam, 1993 (c) Erdelyi-Toth, V.; Gyergyay, F.;
Szamel, I.; Pap, E.; Kralovanszky, J.; Bojti, E.; Gsorgo, M.; Drabant,
S.; Klebovich, I. Anti-Cancer Drugs 1997, 8, 603.
(2) (a) Oehlrich, D.; Berthelot, D. J.-C.; Gijsen, H. J. M. J. Med.
Chem. 2011, 54, 699. (b) Chen, J.; Lu, M.-M.; Liu, B.; Chen, Z.; Li, Q.-
B.; Tao, L.-J.; Hu, G.-Y. Bioorg. Med. Chem. Lett. 2012, 22, 2300. (c) Li,
P.; Liu, L.-J.; Liu, J.-T. Org. Biomol. Chem. 2011, 9, 74. (d) Yi, H.;
Song, L. P.; Wang, W.; Liu, J. N.; Zhu, S. Z.; Deng, H. M.; Shao, M.
Chem. Commun. 2010, 46, 6941. (e) Gille, S.; Ferry, A.; Billard, T.;
Langlois, B. R. J. Org. Chem. 2003, 68, 8933.
(3) Grunewald, G. L.; Galdwell, T. M.; Li, Q. F.; Criscione, K. R. J.
Med. Chem. 1999, 42, 3315.
(4) (a) Gille, S.; Ferry, A.; Billard, T.; Langlois, B. R. J. Org. Chem.
2003, 68, 8932. (b) Jiang, J. L.; Devita, R. J.; Doss, G. A.; Goulet, M. t.;
Wyvratt, M. J. J. Am. Chem. Soc. 1999, 121, 593. (c) Yeh, P.-P.;
Daniels, D. S. B.; Cordes, D. B.; Slawin, A. M. Z.; Smith, A. D. Org.
Lett. 2014, 16, 964. (d) Troconiz, G. F. D.; Retana, A. M. O. D.;
Pascual, S.; Ezpeleta, J. M.; Palacios, F. Eur. J. Org. Chem. 2013, 25,
5614. (e) Zhao, Q.-Y.; Yuan, Z.-L.; Shi, M. Adv. Synth. Catal. 2011,
353, 637.
(5) (a) Breslow, R. J. Am. Chem. Soc. 1958, 80, 3719. (b) Ugai, T.;
Tanaka, S.; Dokawa, S. J. Pharm. Soc. Jpn. 1943, 63, 296. (c) Stetter,
H.; Schreckenberg, M. Angew. Chem., Int. Ed. 1973, 12, 81.
(6) Chow, K. Y.-K.; Bode, J. W. J. Am. Chem. Soc. 2004, 126, 8126.
(7) Reynolds, N. T.; Alaniz, J. R. D.; Rovis, T. J. Am. Chem. Soc. 2004,
126, 9518.
(8) (a) Burstein, C.; Glorius, F. Angew. Chem., Int. Ed. 2004, 43,
6205. (b) Sohn, S. S.; Rosen, E. L.; Bode, J. W. J. Am. Chem. Soc. 2004,
126, 14370.
(9) (a) Zhang, Y.-R.; He, L.; Wu, X.; Shao, P.-L.; Ye, S. Org. Lett.
2008, 10, 277. (b) Duguet, N.; Campbell, C. D.; Slawin, A. M. Z.;
Smith, A. D. Org. Biomol. Chem. 2008, 6, 1108.
(10) (a) Grasa, G. A.; Kissling, R. M.; Nolan, S. P. Org. Lett. 2002, 4,
3583. (b) Connor, E. F.; Nyce, G. W.; Myers, M.; Möck, A.; Hedrick,
J. L. J. Am. Chem. Soc. 2002, 124, 914. (c) Ryan, S. J.; Candish, L.;
Lupton, D. W. J. Am. Chem. Soc. 2009, 131, 14176. (d) Hao, L.; Du,
Y.; Lv, H.; Chen, X.; Jiang, H.; Shao, Y.; Chi, Y. R. Org. Lett. 2012, 14,
2154. (e) Fu, Z.; Xu, J.; Zhu, T.; Leong, W. W. Y.; Chi, Y. R. Nat.
Chem. 2013, 5, 835. (f) Lee, A.; Younai, A.; Price, C. K.; Izquierdo, J.;
Mishra, R. K.; Scheidt, K. A. J. Am. Chem. Soc. 2014, 136, 10589.
(g) Chen, X.-Y.; Gao, Z.-H.; Song, C.-Y.; Zhang, C.-L.; Wang, Z.-X.;
Ye, S. Angew. Chem., Int. Ed. 2014, 53, 11611.
(11) Chen, X.-Y.; Ye, S. Org. Biomol. Chem. 2013, 11, 7991.
(12) For reviews on NHC catalysis, see: (a) Enders, D.; Balensiefer,
T. Acc. Chem. Res. 2004, 37, 534. (b) Enders, D.; Niemeier, O.;
Henseler, A. Chem. Rev. 2007, 107, 5606. (c) Moore, J. L.; Rovis, T.
Top. Curr. Chem. 2010, 291, 77.
(13) (a) Boger, D. L.; Kasper, A. M. J. Am. Chem. Soc. 1989, 111,
1517. (b) Shi, Z. G.; Tong, Q. J.; Leong, W. W. Y.; Zhong, G. F.
Chem.Eur. J. 2012, 18, 9802. (c) Esquivias, J.; Arrayas, R. G.;
Carretero, J. C. J. Am. Chem. Soc. 2007, 129, 1480. (d) Jin, Z. C.; Yang,
R. J.; Du, Y.; Tiwari, B.; Ganguly, R.; Chi, Y. R. Org. Lett. 2012, 14,
3226. (e) Han, B.; Li, J.-L.; Ma, C.; Zhang, S.-J.; Chen, Y.-C. Angew.
Chem., Int. Ed. 2008, 47, 9971. (f) Han, B.; He, Z.-Q.; Li, J.-L.; Li, R.;
Jiang, K.; Liu, T.-Y.; Chen, Y.-C. Angew. Chem., Int. Ed. 2009, 48, 5474.
(g) Shi, Z. G.; Yu, P. Y.; Loh, T.-P.; Zhong, G. F. Angew. Chem., Int. Ed.
2012, 51, 7825. (h) He, L.; Laurent, G.; Retailleau, P.; Folleas, B.;
Brayer, J.-L.; Masson, G. Angew. Chem., Int. Ed. 2013, 52, 11088.
(i) Feng, X.; Ma, C.; Yin, X.; Li, R.; Dong, L.; Chen, Y.-C. Angew.
Chem., Int. Ed. 2013, 52, 14173. (j) Simal, C.; Lebl, T.; Slawin, A. M.
Z.; Smith, A. D. Angew. Chem., Int. Ed. 2012, 51, 3653.
(14) (a) He, M.; Struble, R. J.; Bode, J. W. J. Am. Chem. Soc. 2006,
128, 8418. (b) He, M.; Uc, G. J.; Bode, J. W. J. Am. Chem. Soc. 2006,
128, 15088. (c) Kaeobamrung, J.; Kozlowski, M. C.; Bode, J. W. Proc.
Natl. Acad. Sci. U. S. A. 2010, 107, 20661. (d) Kravina, A. G.;
Mahatthananchai, J.; Bode, J. W. Angew. Chem., Int. Ed. 2012, 51, 9433.

5904

DOI: 10.1021/acs.joc.5b00232
J. Org. Chem. 2015, 80, 5900−5905

Note

The Journal of Organic Chemistry

(15) (a) Hao, L.; Du, Y.; Lv, H.; Chen, X.; Jiang, H.; Shao, Y.; Chi, Y.
R. Org. Lett. 2012, 14, 2154. (b) Hao, L.; Chen, S. J.; Xu, J. F.; Tiwari,
B.; Fu, Z. Q.; Li, T.; Lim, J.; Chi, Y. R. Org. Lett. 2013, 15, 4956.
(16) (a) Jian, T.-Y.; Shao, P.-L.; Ye, S. Chem. Commun. 2011, 47,
2381. (b) Jian, T.-Y.; Sun, L.-H.; Ye, S. Chem. Commun. 2012, 48,
10907.
(17) Wang, X.-N.; Shao, P.-L.; Lv, H.; Ye, S. Org. Lett. 2009, 11,
4029.
(18) For
the nonenantioselective synthesis triﬂuoromethylated
dihydropyridinones see: (a) Palacios, F.; Retana, A. M. O. D.;
Pascual, S.; Troconiz, G. F. D.; Ezpeleta, J. M. Eur. J. Org. Chem. 2010,
34, 6618. (b) Wang, P. Y.; Song, L. P.; Yi, H.; Zhang, M.; Zhu, S. Z.;
Deng, H. M.; Shao, M. Tetrahedron Lett. 2010, 51, 3975. (c) Yi, H.;
Song, L. P.; Wang, W.; Liu, J. N.; Zhu, S. Z.; Deng, H. M.; Shao, M.
Chem. Commun. 2010, 46, 6941.
(19) (a) Kerr, M. S.; Read de Alaniz, J.; Rovis, T. J. Org. Chem. 2005,
70, 5725. (b) He, M.; Struble, J. R.; Bode, J. W. J. Am. Chem. Soc. 2006,
128, 8418.
(20) (a) Scott, E. A.; Jessada, M.; Jeffrey, W. B.; Marisa, C. K. J. Am.
Chem. Soc. 2012, 134, 12098. (b) Li, M. Y.; Fei, W.; Richmond, L.;
Yun, B. L.; Kuo, W. H.; Guo, F. Z. J. Org. Chem. 2014, 16, 38872.
(21) (a) Kerr, M. S.; DeAlaniz, J. R.; Rovis, T. J. Am. Chem. Soc. 2002,
124, 10298. (b) He, M.; Struble, J. R.; Bode, J. W. J. Am. Chem. Soc.
2005, 44, 4564. (c) Okada, A.; Shibuguchi, T.; Ohshima, T.; Masu, H.;
Yanaguchi, K.; Shibasaki, M. Angew. Chem., Int. Ed. 2012, 51, 9433.
(d) Qing, J. L.; Gregory, P. T. J. Org. Chem. 2014, 16, 1382.

5905

DOI: 10.1021/acs.joc.5b00232
J. Org. Chem. 2015, 80, 5900−5905

